FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050931381> ?p ?o ?g. }

• W2050931381 endingPage "1108" @default.
• W2050931381 startingPage "1100" @default.
• W2050931381 abstract "Binding of bacterial cell wall components to CD14 and co-receptors on myeloid cells results in cellular activation and production of proinflammatory mediators. A recombinant anti-CD14 monoclonal antibody (IC14) has been shown to decrease lipopolysaccharide-induced responses in animal and human models of endotoxemia. This study was performed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical pharmacology of IC14 in patients with severe sepsis.Randomized, double-blind, placebo-controlled, dose-ranging, multiple-center trial.Six medical and surgical intensive care units located in Germany and The Netherlands.Forty patients with severe sepsis.IC14 was administered intravenously to eight patients/cohort as single (1 mg/kg or 4 mg/kg) or multiple doses (4 mg/kg daily for 4 days, or 4 mg/kg on day 1 followed by 2 mg/kg daily for 3 days). A placebo group (two patients/cohort) was also included.The overall incidence and types of adverse events were similar among treatment groups. One patient in the group receiving multiple-dose IC14 4 mg/kg daily for 4 days experienced an anaphylactic reaction after receiving the first dose of study drug. IC14 did not induce antibody formation or increase the incidence of secondary bacterial infection. A mean IC14 serum concentration of approximately 1 microg/mL was required to achieve 50% of maximum membrane-bound CD14 receptor occupancy on peripheral blood monocytes. The pattern of proinflammatory and anti-inflammatory cytokines, chemokine, soluble receptor, soluble E-selectin, and acute phase proteins in response to treatment was highly variable by patient and IC14 treatment group.Single and multiple doses of IC14 were generally well tolerated and did not induce antibody formation or increase the incidence of secondary bacterial infection. The results suggest that CD14 blockade with IC14 warrants further clinical investigation to determine its ability to attenuate the proinflammatory response due to infection." @default.
• W2050931381 created "2016-06-24" @default.
• W2050931381 creator A5012398274 @default.
• W2050931381 creator A5019348361 @default.
• W2050931381 creator A5023876294 @default.
• W2050931381 creator A5025379878 @default.
• W2050931381 creator A5032322983 @default.
• W2050931381 creator A5057943412 @default.
• W2050931381 creator A5067372008 @default.
• W2050931381 creator A5074925762 @default.
• W2050931381 creator A5076211886 @default.
• W2050931381 creator A5079036572 @default.
• W2050931381 creator A5079834698 @default.
• W2050931381 creator A5081164839 @default.
• W2050931381 date "2004-05-01" @default.
• W2050931381 modified "2023-09-27" @default.
• W2050931381 title "CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)*" @default.
• W2050931381 cites W1499532983 @default.
• W2050931381 cites W1518906031 @default.
• W2050931381 cites W1820991472 @default.
• W2050931381 cites W1898252364 @default.
• W2050931381 cites W1901081243 @default.
• W2050931381 cites W1926429898 @default.
• W2050931381 cites W1968713831 @default.
• W2050931381 cites W1977905350 @default.
• W2050931381 cites W1982345842 @default.
• W2050931381 cites W1983579326 @default.
• W2050931381 cites W1991109223 @default.
• W2050931381 cites W2004985996 @default.
• W2050931381 cites W2021418970 @default.
• W2050931381 cites W2024858122 @default.
• W2050931381 cites W2041977750 @default.
• W2050931381 cites W2049927822 @default.
• W2050931381 cites W2051596822 @default.
• W2050931381 cites W2058352235 @default.
• W2050931381 cites W2066362538 @default.
• W2050931381 cites W2067338751 @default.
• W2050931381 cites W2067394045 @default.
• W2050931381 cites W2075512720 @default.
• W2050931381 cites W2078324582 @default.
• W2050931381 cites W2085208748 @default.
• W2050931381 cites W2086330271 @default.
• W2050931381 cites W2093816949 @default.
• W2050931381 cites W2110052216 @default.
• W2050931381 cites W2121544368 @default.
• W2050931381 cites W2123883239 @default.
• W2050931381 cites W2132413368 @default.
• W2050931381 cites W2133369735 @default.
• W2050931381 cites W2145564764 @default.
• W2050931381 cites W2145577370 @default.
• W2050931381 cites W2147159596 @default.
• W2050931381 cites W2149466293 @default.
• W2050931381 cites W2157282632 @default.
• W2050931381 cites W2158028015 @default.
• W2050931381 cites W2166349511 @default.
• W2050931381 cites W2169512162 @default.
• W2050931381 cites W2171765848 @default.
• W2050931381 cites W2227468111 @default.
• W2050931381 cites W4251342124 @default.
• W2050931381 cites W4293242440 @default.
• W2050931381 doi "https://doi.org/10.1097/01.ccm.0000124870.42312.c4" @default.
• W2050931381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15190957" @default.
• W2050931381 hasPublicationYear "2004" @default.
• W2050931381 type Work @default.
• W2050931381 sameAs 2050931381 @default.
• W2050931381 citedByCount "65" @default.
• W2050931381 countsByYear W20509313812012 @default.
• W2050931381 countsByYear W20509313812013 @default.
• W2050931381 countsByYear W20509313812014 @default.
• W2050931381 countsByYear W20509313812015 @default.
• W2050931381 countsByYear W20509313812016 @default.
• W2050931381 countsByYear W20509313812017 @default.
• W2050931381 countsByYear W20509313812018 @default.
• W2050931381 countsByYear W20509313812019 @default.
• W2050931381 countsByYear W20509313812020 @default.
• W2050931381 countsByYear W20509313812021 @default.
• W2050931381 countsByYear W20509313812022 @default.
• W2050931381 crossrefType "journal-article" @default.
• W2050931381 hasAuthorship W2050931381A5012398274 @default.
• W2050931381 hasAuthorship W2050931381A5019348361 @default.
• W2050931381 hasAuthorship W2050931381A5023876294 @default.
• W2050931381 hasAuthorship W2050931381A5025379878 @default.
• W2050931381 hasAuthorship W2050931381A5032322983 @default.
• W2050931381 hasAuthorship W2050931381A5057943412 @default.
• W2050931381 hasAuthorship W2050931381A5067372008 @default.
• W2050931381 hasAuthorship W2050931381A5074925762 @default.
• W2050931381 hasAuthorship W2050931381A5076211886 @default.
• W2050931381 hasAuthorship W2050931381A5079036572 @default.
• W2050931381 hasAuthorship W2050931381A5079834698 @default.
• W2050931381 hasAuthorship W2050931381A5081164839 @default.
• W2050931381 hasConcept C111113717 @default.
• W2050931381 hasConcept C112705442 @default.
• W2050931381 hasConcept C126322002 @default.
• W2050931381 hasConcept C142724271 @default.
• W2050931381 hasConcept C164027704 @default.
• W2050931381 hasConcept C170493617 @default.
• W2050931381 hasConcept C203014093 @default.
• W2050931381 hasConcept C204787440 @default.

• next